INS and cancer: For sufficient levels of insulin in portal circulation to suppress hepatic gluconeogenesis, supraphysiologic concentrations of insulin should be reached in systemic circulation.23 The iatrogenic insulin excess and possible mutagenic effect of insulin or insulin analogue might account for some increased cancer risk.1,34–36